The Chart of the Day belongs to Kite Pharma Inc. (NASDAQ:KITE). I found the biopharmaceutical stock by using Barchart to sort the Russell 3000 Index stocks first for a Weighted Alpha of 50.00+ or more, then for technical buy signals of 80% or better, then again for a 50-100 Day MACD Oscillator but and eliminated stocks trading less than 100K share a day. Finally, I always use the Flipchart feature to review the charts. Since the Trend Spotter signaled a buy on 10/7 the stock gained 27.01%.

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.

The status of Barchart’s Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

  • 100% Barchart technical buy signals
  • 84.10+ Weighted Alpha
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 10 new highs and up 29.81% in the last month
  • Relative Strength Index 74.33%
  • Barchart computes a technical support level at 73.58
  • Recently traded at 81.73 with a 50 day moving average of 64.52

    • Fundamental factors:

  • Market Cap $3.52 billion
  • Revenue expected to be up 16.50% next year
  • Earnings estimates are all over the chart so I feel are unreliable
  • Wall Street analysts still issued 4 strong buy, 2 buy and 1 hold recommendation on the stock
  • The individual investors on Motley Fool voted 87 to 9 for the stock to beat the market

    • The 20-50 Day MACD Oscillator has been a reliable technical trading strategy for this stock.

    Print Friendly, PDF & Email

    Related Posts